Skip to main content
Erschienen in: Molecular Cancer 1/2014

Open Access 01.12.2014 | Research

TopBP1 and Claspin contribute to the radioresistance of lung cancer brain metastases

verfasst von: Seung Ho Choi, Heekyoung Yang, Seung Ho Lee, Joo-Hyun Ki, Do-Hyun Nam, Hae Yong Yoo

Erschienen in: Molecular Cancer | Ausgabe 1/2014

Abstract

Background

Radiation therapy is one of the most effective therapeutic tools for brain metastasis. However, it is inevitable that some cancer cells become resistant to radiation. This study is focused on the identification of genes associated with radioresistance in metastatic brain tumor from lung cancer and the functional examination of the selected genes with regards to altered sensitivity of cancer cells to radiation.

Methods

After establishing radioresistant cells from the xenograft model, we explored the significant transcriptional changes by performing DNA microarray profiling. Functional analyses in vitro and in vivo performed to validate the gene responsible for radioresistance.

Results

Transcriptional changes induced by radiation therapy are much more extensive in H460 cells than in PC14PE6 cells. The expression levels of TopBP1 and Claspin were increased in the cancer cells that survived radiation therapy. Depletion of TopBP1 or Claspin using shRNA showed an enhancement of sensitivity to radiation in radioresistant lung cancer cells (PC14PE6). Moreover, increased levels of TopBP1 or Claspin endowed cells a higher resistance to radiation. In xenograft models, the knock-down of TopBP1 or Claspin significantly prolonged the median survival time post radiation therapy.

Conclusions

We analyzed the gene expression profiles of the radiosensitive cells and the radioresistant cells to define a set of genes that may be involved in endowing lung cancer cells radioresistance post brain metastasis. Functional analyses indicated that the expression TopBP1 and Claspin positively affects the survival of cancer cells and thus negatively the xenograft metastasis model animals in response to radiation. These results show that TopBP1 and Claspin can be potential targets for the enhanced efficacy of radiotherapy.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1476-4598-13-211) contains supplementary material, which is available to authorized users.
Seung Ho Choi, Heekyoung Yang contributed equally to this work.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SHC and HY performed most of the experiments; SHC, DHN and HYY analyzed data; SHL and JHK helped with all experiments and contributed to implementation and interpretation of the results; DHN and HYY outlined the experimental design of the study; SHC and HYY contributed intellectually toward the design and wrote the manuscript. All authors read and approved the final manuscript.
Abkürzungen
MBT
Metastatic brain tumor
IR
Ionizing radiation
TopBP1
Topoisomerase IIβ binding protein 1
DDR
DNA damage response.

Background

Brain metastases occur in 20 to 40% of all patients with cancer [1]. The problem is particularly challenging for lung cancer patients as they often present with multiple brain metastases. Even though multiple chemotherapeutic agents have been studied for treatment of metastatic brain tumors (MBTs), their clinical availability and effectiveness are still limited. In these circumstances, whole-brain radiation therapy has been used in the management of brain metastases [1]. In fact, radiation therapy or stereotactic radiosurgery often turn out to be the only available tools in the cases of multiple MBTs. However, the frequent resistance to radiation resulting in recurrence leads to treatment failure in a substantial fraction of MBT patients.
Recently, various checkpoint mechanisms have received much attention in association with genetic damages from UV light or ionizing radiation (IR). DNA damage checkpoints are important parts of signal-transduction pathways that delay or arrest cell cycle progression in response to the damage. Originally, checkpoints aid maintaining genomic integrity and cell survival. However, these mechanisms can be used by cancer cells to evade apoptosis from DNA injury, resulting in acquiring resistance to irradiation [2, 3]. There are several reports suggesting that the checkpoint can be exploited to enhance radiosensitivity [4, 5]. As a mediator, topoisomerase IIβ binding protein 1 (TopBP1) is an essential co-activator of ATR [6]. In addition, this protein has a direct and essential role in the pathway that connects ATM to ATR [7]. Claspin was identified as a Chk1-interacting protein and an important regulator of Chk1 activation [8, 9].
Cells with functionally defective components of DNA damage checkpoint pathways show cell cycle checkpoint defects, and an increased sensitivity to IR and other DNA damage agents [2, 10]. This latter observation highlights components of these DNA damage checkpoint pathways as potential therapeutic targets for enhancing the sensitivity of tumor cells to the radiotherapeutic agents [11]. Tumor cell specific checkpoint mechanisms for DNA damage in response to IR can thus provide clues to problems of radioresistance.
In the present study, we sought to genes associated with radioresistance in metastatic brain tumor and to investigate how they can be targeted for enhanced susceptibility of carcinoma cells to radiation. We analyzed the gene expression profiles of lung cancer cells with and without radiation treatment using xenograft models of lung cancer brain metastasis. We found that the expression levels of TopBP1 and Claspin were significantly increased in the surviving cancer cells after radiation therapy compared to untreated cells. Consistently, depletion of TopBP1 or Claspin in lung cancer cells showed an enhancement of sensitivity to radiation. In xenograft models, the knock-down of TopBP1 or Claspin significantly prolonged the median survival time in response to radiotherapy. Therefore TopBP1 and Claspin are potential therapeutic targets for overcoming the limitation of radiotherapy for MBT.

Results and discussion

Induction of radioresistance using lung cancer brain metastases xenograft

We assessed radiosensitivity of lung cancer cell lines (PC14PE6 and H460) with various doses of radiation. The clonogenic survival assays revealed that both cell lines showed clear radiation sensitivity in a dose-dependent manner, and the survival fraction of PC14PE6 showed 0.4 at 2.5 Gy whereas the survival fraction of H460 cells was more severely reduced down to 0.04 at 2.5 Gy (Figure 1A). These reduced radiation sensitivity of PC14PE6 indicated that PC14PE6 cells were relatively more resistant to radiation than H460 cells. We made lung cancer brain metastases xenograft models using PC14PE6 and H460 cells and tested whether tumor cells in xenograft models acquired radioresistance after radiotherapy. As shown in Figure 1B, xenografted mice models were exposed to radiation once, and the tumor cell mass was excised and cultured in vitro again. To validate whether radiosensitivity of tumor cells were changed, the tumor cells were irradiated with a range of radiation doses (5–20 Gy). Survival representing resistance to radiation was examined by cell proliferation assay and shown by percent of viability to non-irradiated cells (Figure 1C & D). Initially H460 cells have been less resistant to radiation, but cells from irradiated tumor cells (H460-5Gy and H460-10Gy) acquired radioresistance of over 90% of the survival rate (Figure 1C). H460-10Gy cells were even more radioresistant than H460 and H460-5Gy. These results show that radiosensitive H460 cells acquired radioresistance in a dose dependent manner. However, PC14PE6, originally more radioresistant than H460 did not show additional increase of resistance regardless of the radiation dose (Figure 1D).

Alteration in gene expression profiles

After establishing radioresistant cells from the xenograft model, we explored the significant transcriptional changes by performing DNA microarray profiling. Using a filter criterion of at least 2-fold change with p < 0.05, the numbers of genes with changes in expression in H460-10Gy and PC14PE6-20Gy cells were determined: 385 genes increased and 329 genes decreased in H460 while 76 genes increased and 98 genes decreased in PC14PE6. Between the two cell lines, 64 of the increased genes and 63 of the decreased genes overlapped. These results are presented in a Venn diagram (Figure 2A). In particular, the number of affected genes in H460-10Gy cells was 4.1 fold higher than that in PC14PE6-20Gy. These results showed that transcriptional changes induced by radiation therapy are more extensive in radiosensitive cells (H460) than in resistant cells (PC14PE6). Functional annotation of the genes was carried out using gene ontology-based biological property analysis. The genes were categorized into 15 functional groups (Figure 2B & C). Most of the changed genes in the two cell lines were associated with cell differentiation, proliferation and cell cycle. The genes with significant changes in expression are listed in Additional file 1: Table S1-S4.

Enhanced radiosensitivity from depletion of TopBP1 and Claspin

Genes involved in cellular response to DSBs are the major targets for cancer cell death [12]. Specifically, functional defects in DNA damage checkpoint pathways show an increased sensitivity to radiation [2, 10, 13], which led us to focus on the DNA Damage response (DDR) signaling pathway for subsequent analyses. The genes with expression change in DNA damage checkpoint pathway are listed in Additional file 1: Table S5. Notably, genes from H460-10Gy outnumber those from PC14E6-20Gy. We chose TopBP1 and Claspin genes as our targets for functional analysis as they play important roles for activating Chk1 in DDR pathway [6, 8, 14]. In particular, since Chk1 inhibition using inhibitors showed an enhancement of radiation sensitivity [13, 15], it is worth analyzing the role of genes upstream to Chk1 with regards to radiosensitivity. Chk1 is a well-established ATR target involved in DDR and normal cell cycle progression and thus represents a potential pharmacological target in the development of anti-cancer therapeutic agents [16, 17].
To confirm and validate the findings obtained from our microarray analysis, we used the radioresistant PC14PE6 cells and established stable lines in which TopBP1 and Claspin were regulated by shRNA via doxycycline treatment. It was confirmed that the mRNA levels of the two genes decreased by doxycycline treatment compared to untreated PC14PE6 cells (Additional file 1: Figure S1A & B). Induction of shRNA virtually completely abolished the expression of TopBP1 and Claspin (Figure 3A). It has been shown that TopBP1 and Claspin play an essential role in Chk1 activation/phosphorylation in response to DNA damage [6, 14]. We next examined the phosphorylation of Chk1 in response to irradiation after knockdown of TopBP1 and Claspin. As shown in Figure 3A, depletion of TopBP1 or Claspin abolished Chk1 phosphorylation as previously reported [6, 7, 14]. Immunocytochemistry of γ-H2AX and TopBP1 demonstrated that γ-H2AX foci were significantly decreased and the signals for TopBP1 were scantly detected after the depletion of TopBP1 (Additional file 1: Figure S1C).
We performed clonogenic survival assay to measure the change in sensitivity to radiation in these stable cell lines. The PC14PE6/shLuc cells showed a similar sensitivity to irradiation in comparison to original PC14PE6 cells (Figure 3Ba). TopBP1 and Claspin knockdown cells showed a higher sensitivity than control cells. The decrease in survival was particularly dramatic at higher dose of IR (e.g. 4 Gy) than at lower dose of IR (< 2 Gy) for both PC14PE6/shTopBP1 and PC14PE6/shClaspin cells (Figure 3Bb & c). Our results are consistent with a previous report describing an enhanced susceptibility to radiation in cells with down-regulated Chk1 [13].

Enhanced radioresistance in cells from overexpression of TopBP1 or Claspin

The expression levels of TopBP1 and Claspin increased in induced radioresistant H460-10Gy cells. To clarify and further evaluate their roles with radioresistance, TopBP1, Claspin, and Chk1 were overexpressed in three independent cell lines, H460, H23, and U2OS which are all highly radiosensitive compared to PC14PE6 (Figure 3C & Additional file 1: Figure S2). The overexpression of each gene was examined by immunoblot (Figure 3C). In clonogenic assay, GFP expression vector was used as a control. In H460 and H23 cells, overexpressing TopBP1 showed higher survival (over 50%) than control cells after 2 Gy IR exposure (Figure 3D). In U2OS, the number of surviving colonies increased by about 20% compared to the control. These results indicate that overexpression of TopBP1, Claspin, and Chk1 induces radioresistance, consistent with the microarray data.

Extended survival of brain metastasized mice by TopBP1 or Claspin knockdown

Based on results from in vitro functional assays, we hypothesized that TopBP1 or Claspin would be potential target genes in lung cancer brain metastasis models (Figure 4). We thus sought to estimate the effects of TopBP1 and Claspin knockdown based on the survival of lung cancer brain metastasis xenograft model animals in response to irradiation. We produced orthotopic xenograft animals with injection of PC14PE6/shTopBP1 or PC14PE6/shClaspin cells into the brain of athymic nude mice. Tumor-bearing mice were treated with doxycycline and/or radiation therapy as illustrated (Figure 4A). As shown in Figure 4B, without irradiation, there was no difference in survival rates between TopBP1-inhibited (i.e. doxycycline-treated) group and TopBP1-expressing group. The median survival time was 19 days. In contrast, when irradiated, xenografted mice with inhibited expression of TopBP1 showed a higher survival rate than the control mice with the mean life span of 42 days post injection (Figure 4C). In case of Claspin knockdown mouse, the survival also extended with irradiation and doxycycline treatment although the effect was not as dramatic as in the case of TopBP1 knockdown. Lung cancer brain metastasis models in this study do not represent patients completely. Radiotherapy did not mimic patient dosing and fractionation schedules for limitation of animal models. In sum, xenotransplant analysis further confirmed the proposed role of TopBP1 or Claspin in DDR response and acquisition of radioresistance.

Conclusions

In this study, we comparatively analyzed the gene expression profiles of the radiosensitive cells and the radioresistant cells to define a set of genes that may be involved in endowing lung cancer cells radioresistance post brain metastasis. Functional analyses in vitro and in vivo indicated that the expression TopBP1 and Claspin positively affects the survival of cancer cells and thus negatively the xenograft metastasis model animals. This is consistent with results from our previous study which demonstrated elevated expression levels of DNA damage checkpoint genes in radioresistant lung cancer cell lines compared to the levels in radiosensitive cell lines [18]. The expression pattern of DNA damage checkpoint genes thus could be useful for diagnosis and prognosis of brain metastasis and be promising targets for overcoming the radio-resistance in brain metastasis.

Methods

Cell culture and cell lines

Human non-small cell lung cancer (NSCLC) cell lines H23, H460, and human osteosarcoma cell (U2OS) (American Type Culture Collection) were maintained in RPMI 1640 medium containing 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin, and PC14PE6, kindly provided by MD Anderson Cancer Center was maintained in Eagle’s minimal essential medium (MEM) containing 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37 °C and 5% CO2. Cell lines were regularly tested for mycoplasma infection using the MycoAlert mycoplasma detection kit (Lonza). Isolated PC14PE6 and H460 cells from xenograft mouse brains were immediately used to assay for the cell viability after dissociation procedure.

Transfection and stable cell lines

For overexpression of TopBP1, Claspin, and Chk1 in H23, H460 or U2OS cell lines, each cell lines were transfected with expression vectors by electroporation using Cell Line Nucleofector® Kit V with the Amaxa Nucleofector I system (Lonza). Stable cell lines of tetracycline-regulated expression of a short hairpin RNA were generated as previously described [13]. For shRNA induction, cells were seeded to achieve 30%-50% confluency on the day of induction and doxycycline was added into the culture medium at 1 μg/ml.

Western blotting

Cells were lysed and prepared for Western blotting analysis as previously described [19]. Anti-Chk1 and anti-α-tubulin antibodies were purchased from Santa Cruz Biotechnology. Anti-Claspin, anti-Chk1 phospho-Ser317, anti-Chk2 phospho-Thr68 and anti-γ-H2AX antibodies were obtained from Cell Signaling Technology. Anti-TopBP1 was obtained from Abcam. The secondary antibodies Cy3-conjugated anti-mouse IgG and FITC-conjugated anti-rabbit IgG for immunofluorescence were purchased from Jackson Immunoresearch.

RNA interference

siRNAs were obtained from Genolution Pharma, Korea. The sequences of the siRNAs targeting TopBP1 were: #1, CAGAAUUGUUGGUCCUCAAdTdT and #2, CGAUAGAGGAGACUCAUGAdTdT. The sequences of Claspin siRNA 1 and siRNA 2 were GGAAAGAAAGGCAGCCAGAdTdT and CCUUGCUUAGAGCUGAGUCdTdT, respectively. The control luciferase siRNA sequence was GTTACGCTGAGTACTTCGAAA. After the test of mRNA knockdown efficacy, plasmids expressing shRNA were constructed by shRNA cloning service from Genolution.

Cell proliferation assay and clonogenic survival assay

Cell proliferation was analyzed with Cell Counting Kit 8 (Dojindo Molecular Technology) and clonogenic survival assay was performed as previously described [13]. Cell proliferation was expressed as a percentage of the absorbance obtained in irradiated cells relative to that in untreated control cells. Each experiment in triplicates was repeated three times. Error bars represent the standard deviation.

Orthotopic lung cancer brain metastases xenograft studies

All experiments were conducted in accordance with the Institute Laboratory Animal Research Guide for the Care and Use of Laboratory Animals and within the protocols approved by the appropriate Institutional Review Boards at the Samsung Medical Center (Seoul, Korea). Female athymic nude mice, 7 weeks of age were used for this study. Production of orthotopic lung cancer brain metastases models were performed as previously described [13]. Mock-irradiated or irradiated mice were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine and restrained in custom-designed mice jig. Whole brain irradiation (15 Gy) was performed after 2 weeks. To induce knockdown of TopBP1 and Claspin, doxycycline, which was formulated in 5% sucrose, was administered for 5 days in drinking water from 12 days after tumor cells implantation at a dose of 1 mg/ml.

RNA expression array and data analysis

RNA expression array was performed as previously described [18]. RNA was transcribed into cDNA and hybridized onto Affymetrix GeneChip HG-U133Plus2.0 according to the Affymetrix GeneChip Expression Analysis Technical Manual. The gene expression CEL files were normalized using the Robust Multichip averaging procedure. The dataset was normalized using Central Tendency Median Normalization. Expression array data were deposited at http://​tbi.​skku.​edu/​microarray/​smc/​yoo-20140106.

Statistical analysis

The survival analysis of xenograft model was performed using the Kaplan-Meier and log rank tests (SPSS statistical software, version 18.0). Increasing life span (ILS, %) compared to median survival of negative control was calculated, and statistical comparison was analyzed with one-way analysis of variance (ANOVA) followed by the lease significant difference (LSD) test. In vitro experimental data were obtained from experiments repeated three times with triplicates. Mean values were calculated and significance was determined using the Student’s two tailed test. P values < 0.05 were considered statistically significant.

Acknowledgments

We appreciate helpful discussion and comments from Prof. J. Kim (Ewha Womans University). We are also grateful to our colleagues in the laboratory for comments on the manuscript. This work was supported by grants from the Korea Healthcare technology R&D Project, Ministry for Health & Welfare Affairs, Republic of Korea (A090253 and A092255), the National Research Foundation of Korea (NRF-2013R1A1A2060410) and Samsung Biomedical Research Institute (GE1-B2-071).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
The Creative Commons Public Domain Dedication waiver (https://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SHC and HY performed most of the experiments; SHC, DHN and HYY analyzed data; SHL and JHK helped with all experiments and contributed to implementation and interpretation of the results; DHN and HYY outlined the experimental design of the study; SHC and HYY contributed intellectually toward the design and wrote the manuscript. All authors read and approved the final manuscript.
Anhänge
Literatur
1.
Zurück zum Zitat Patchell RA: The management of brain metastases. Cancer Treat Rev. 2003, 29: 533-540. 10.1016/S0305-7372(03)00105-1CrossRefPubMed Patchell RA: The management of brain metastases. Cancer Treat Rev. 2003, 29: 533-540. 10.1016/S0305-7372(03)00105-1CrossRefPubMed
2.
Zurück zum Zitat Kastan MB, Bartek J: Cell-cycle checkpoints and cancer. Nature. 2004, 432: 316-323. 10.1038/nature03097CrossRefPubMed Kastan MB, Bartek J: Cell-cycle checkpoints and cancer. Nature. 2004, 432: 316-323. 10.1038/nature03097CrossRefPubMed
3.
Zurück zum Zitat Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004, 73: 39-85. 10.1146/annurev.biochem.73.011303.073723CrossRefPubMed Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004, 73: 39-85. 10.1146/annurev.biochem.73.011303.073723CrossRefPubMed
4.
Zurück zum Zitat Fernet M, Megnin-Chanet F, Hall J, Favaudon V: Control of the G2/M checkpoints after exposure to low doses of ionising radiation: implications for hyper-radiosensitivity. DNA Repair (Amst). 2010, 9: 48-57. 10.1016/j.dnarep.2009.10.006CrossRef Fernet M, Megnin-Chanet F, Hall J, Favaudon V: Control of the G2/M checkpoints after exposure to low doses of ionising radiation: implications for hyper-radiosensitivity. DNA Repair (Amst). 2010, 9: 48-57. 10.1016/j.dnarep.2009.10.006CrossRef
5.
Zurück zum Zitat Kim YM, Lee YM, Park SY, Pyo H: Ataxia telangiectasia and Rad3-related overexpressing cancer cells induce prolonged G(2) arrest and develop resistance to ionizing radiation. DNA Cell Biol. 2011, 30: 219-227. 10.1089/dna.2010.1141CrossRefPubMed Kim YM, Lee YM, Park SY, Pyo H: Ataxia telangiectasia and Rad3-related overexpressing cancer cells induce prolonged G(2) arrest and develop resistance to ionizing radiation. DNA Cell Biol. 2011, 30: 219-227. 10.1089/dna.2010.1141CrossRefPubMed
6.
Zurück zum Zitat Kumagai A, Lee J, Yoo HY, Dunphy WG: TopBP1 activates the ATR-ATRIP complex. Cell. 2006, 124: 943-955. 10.1016/j.cell.2005.12.041CrossRefPubMed Kumagai A, Lee J, Yoo HY, Dunphy WG: TopBP1 activates the ATR-ATRIP complex. Cell. 2006, 124: 943-955. 10.1016/j.cell.2005.12.041CrossRefPubMed
7.
Zurück zum Zitat Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG: Ataxia-telangiectasia mutated (ATM)-dependent activation of ATR occurs through phosphorylation of TopBP1 by ATM. J Biol Chem. 2007, 282: 17501-17506. 10.1074/jbc.M701770200CrossRefPubMed Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG: Ataxia-telangiectasia mutated (ATM)-dependent activation of ATR occurs through phosphorylation of TopBP1 by ATM. J Biol Chem. 2007, 282: 17501-17506. 10.1074/jbc.M701770200CrossRefPubMed
8.
Zurück zum Zitat Kumagai A, Dunphy WG: Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. Mol Cell. 2000, 6: 839-849. 10.1016/S1097-2765(05)00092-4CrossRefPubMed Kumagai A, Dunphy WG: Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. Mol Cell. 2000, 6: 839-849. 10.1016/S1097-2765(05)00092-4CrossRefPubMed
9.
Zurück zum Zitat Kumagai A, Dunphy WG: Repeated phosphopeptide motifs in Claspin mediate the regulated binding of Chk1. Nat Cell Biol. 2003, 5: 161-165. 10.1038/ncb921CrossRefPubMed Kumagai A, Dunphy WG: Repeated phosphopeptide motifs in Claspin mediate the regulated binding of Chk1. Nat Cell Biol. 2003, 5: 161-165. 10.1038/ncb921CrossRefPubMed
10.
Zurück zum Zitat Shiloh Y: Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu Rev Genet. 1997, 31: 635-662. 10.1146/annurev.genet.31.1.635CrossRefPubMed Shiloh Y: Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu Rev Genet. 1997, 31: 635-662. 10.1146/annurev.genet.31.1.635CrossRefPubMed
11.
Zurück zum Zitat Eastman A: Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem. 2004, 91: 223-231. 10.1002/jcb.10699CrossRefPubMed Eastman A: Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem. 2004, 91: 223-231. 10.1002/jcb.10699CrossRefPubMed
12.
Zurück zum Zitat Lee Y, Katyal S, Downing SM, Zhao J, Russell HR, McKinnon PJ: Neurogenesis requires TopBP1 to prevent catastrophic replicative DNA damage in early progenitors. Nat Neurosci. 2012, 15: 819-826. 10.1038/nn.3097PubMedCentralCrossRefPubMed Lee Y, Katyal S, Downing SM, Zhao J, Russell HR, McKinnon PJ: Neurogenesis requires TopBP1 to prevent catastrophic replicative DNA damage in early progenitors. Nat Neurosci. 2012, 15: 819-826. 10.1038/nn.3097PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Yang H, Yoon SJ, Jin J, Choi SH, Seol HJ, Lee JI, Nam DH, Yoo HY: Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy. Biochem Biophys Res Commun. 2011, 406: 53-58. 10.1016/j.bbrc.2011.01.106CrossRefPubMed Yang H, Yoon SJ, Jin J, Choi SH, Seol HJ, Lee JI, Nam DH, Yoo HY: Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy. Biochem Biophys Res Commun. 2011, 406: 53-58. 10.1016/j.bbrc.2011.01.106CrossRefPubMed
14.
Zurück zum Zitat Liu S, Bekker-Jensen S, Mailand N, Lukas C, Bartek J, Lukas J: Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation. Mol Cell Biol. 2006, 26: 6056-6064. 10.1128/MCB.00492-06PubMedCentralCrossRefPubMed Liu S, Bekker-Jensen S, Mailand N, Lukas C, Bartek J, Lukas J: Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation. Mol Cell Biol. 2006, 26: 6056-6064. 10.1128/MCB.00492-06PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Syljuasen RG, Sorensen CS, Nylandsted J, Lukas C, Lukas J, Bartek J: Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res. 2004, 64: 9035-9040. 10.1158/0008-5472.CAN-04-2434CrossRefPubMed Syljuasen RG, Sorensen CS, Nylandsted J, Lukas C, Lukas J, Bartek J: Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res. 2004, 64: 9035-9040. 10.1158/0008-5472.CAN-04-2434CrossRefPubMed
16.
Zurück zum Zitat Dai Y, Grant S: Methods to study cancer therapeutic drugs that target cell cycle checkpoints. Methods Mol Biol. 2011, 782: 257-304. 10.1007/978-1-61779-273-1_19CrossRefPubMed Dai Y, Grant S: Methods to study cancer therapeutic drugs that target cell cycle checkpoints. Methods Mol Biol. 2011, 782: 257-304. 10.1007/978-1-61779-273-1_19CrossRefPubMed
17.
Zurück zum Zitat Wilsker D, Chung JH, Pradilla I, Petermann E, Helleday T, Bunz F: Targeted mutations in the ATR pathway define agent-specific requirements for cancer cell growth and survival. Mol Cancer Ther. 2012, 11: 98-107. 10.1158/1535-7163.MCT-11-0675PubMedCentralCrossRefPubMed Wilsker D, Chung JH, Pradilla I, Petermann E, Helleday T, Bunz F: Targeted mutations in the ATR pathway define agent-specific requirements for cancer cell growth and survival. Mol Cancer Ther. 2012, 11: 98-107. 10.1158/1535-7163.MCT-11-0675PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Kim KH, Yoo HY, Joo KM, Jung Y, Jin J, Kim Y, Yoon SJ, Choi SH, Seol HJ, Park WY, Nam DH: Time-course analysis of DNA damage response-related genes after in vitro radiation in H460 and H1229 lung cancer cell lines. Exp Mol Med. 2011, 43: 419-426. 10.3858/emm.2011.43.7.046PubMedCentralCrossRefPubMed Kim KH, Yoo HY, Joo KM, Jung Y, Jin J, Kim Y, Yoon SJ, Choi SH, Seol HJ, Park WY, Nam DH: Time-course analysis of DNA damage response-related genes after in vitro radiation in H460 and H1229 lung cancer cell lines. Exp Mol Med. 2011, 43: 419-426. 10.3858/emm.2011.43.7.046PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG: The Mre11-Rad50-Nbs1 complex mediates activation of TopBP1 by ATM. Mol Biol Cell. 2009, 20: 2351-2360. 10.1091/mbc.E08-12-1190PubMedCentralCrossRefPubMed Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG: The Mre11-Rad50-Nbs1 complex mediates activation of TopBP1 by ATM. Mol Biol Cell. 2009, 20: 2351-2360. 10.1091/mbc.E08-12-1190PubMedCentralCrossRefPubMed
Metadaten
Titel
TopBP1 and Claspin contribute to the radioresistance of lung cancer brain metastases
verfasst von
Seung Ho Choi
Heekyoung Yang
Seung Ho Lee
Joo-Hyun Ki
Do-Hyun Nam
Hae Yong Yoo
Publikationsdatum
01.12.2014
Verlag
BioMed Central
Erschienen in
Molecular Cancer / Ausgabe 1/2014
Elektronische ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-211

Weitere Artikel der Ausgabe 1/2014

Molecular Cancer 1/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.